Clik here to view.
Catalent floats $250m public offering to fund Cook Pharmica purchase
Catalent said today that it launched an underwritten public offering for $250 million of its common stock to fund, in part, its $950 million purchase of biologics manufacturer Cook Pharmica. In...
View ArticleClik here to view.
Aspire Capital to acquire $20m worth of Valeritas stock
Valeritas (NSDQ:VLRX) said today that it inked a deal with Aspire Capital Fund to buy $20 million of Valeritas’ common stock. According to the deal, Aspire Capital is slated to purchase common stock at...
View ArticleClik here to view.
BD launches fully-automated diagnostic to fight antimicrobial resistance in...
Becton Dickinson (NYSE: BDX) today launched the first automated phenotypic diagnostic test for infections caused by carbapenemase-producing organisms. The new BD Phoenix CPO test is available as part...
View ArticleClik here to view.
Engage Therapeutics raises $23m Series A for epilepsy drug-device therapy
Summit, N.J.-based Engage Therapeutics said today that it closed a $23 million Series A round to fund a Phase IIb trial of its lead product, Staccato alprazolam. The round was led by TPG Biotech, Adage...
View ArticleClik here to view.
Catalent prices offering to help fund Cook Pharmica acquisition
Catalent today priced an underwritten public offering for 6,395,000 shares of its common stock at $39.10 apiece. The offering will be used to fund, in part, the drug-delivery company’s $950 million...
View ArticleClik here to view.
Baxter launches asset tracking system for infusion pumps
Baxter (NYSE:BAX) today launched the DeviceVue asset tracking solution for hospitals using its Sigma Spectrum infusion system. The product was designed to help clinicians and biomedical engineers...
View ArticleClik here to view.
FDA deals setback to Intarcia for diabetes implant
Privately-held biopharma Intarcia Therapeutics revealed today that the FDA rejected its exenatide implant, ITCA 650, designed to treat Type II diabetes. The company said that it doesn’t think it will...
View ArticleClik here to view.
SteadyMed requests meeting with FDA over rejected application for drug-device...
Shares in SteadyMed (NSDQ:STDY) fell last month after the FDA decided it would not review the new drug application for the company’s drug-device combination product, Trevyent. SteadyMed received a...
View ArticleClik here to view.
Tandem touts adoption of CGM update to t:slim X2 insulin pump
Last month, Tandem Diabetes Care (NSDQ:TNDM) announced that the FDA approved its t:slim X2 insulin pump integrated with Dexcom‘s (NSDQ:DXCM) G5 mobile continuous glucose monitor. The San Diego,...
View ArticleClik here to view.
Cogentix backs Vensica Medical and its needle-free drug delivery system
Cogentix Medical (NASDAQ: CGNT) said today that it invested $2 million in privately-held Vensica Medical and its ultrasound-based, needle-free drug delivery device, VensiCare. Israel-based Vensica...
View ArticleClik here to view.
Insulet “bets big” on Massachusetts with new manufacturing facility in Acton
Insulet (NSDQ:PODD) broke ground at its new manufacturing facility in Acton, Mass. yesterday, hosting a ceremony that featured the state’s governor, Charlie Baker, members of Baker’s administration and...
View ArticleClik here to view.
Why Bigfoot Biomedical’s CEO thinks the diabetes industry has a data problem
Bigfoot Biomedical‘s chief executive is excited about Abbott‘s (NYSE:ABT) latest regulatory win – and it’s not just because the two companies have an established partnership. Yesterday, the FDA...
View ArticleClik here to view.
Novo Nordisk wins FDA nod for fast-acting mealtime insulin
Novo Nordisk (NYSE:NVO) said today that the FDA approved its Fiasp insulin aspart injection. The fast-acting mealtime insulin is designed to improve glycemic control for adults with Type I and Type II...
View ArticleClik here to view.
DarioHealth launches smart diabetes tech in German market
DarioHealth (NSDQ:DRIO) said today that it launched its smart diabetes platform in Germany – the ninth country in which the Israel-based company’s technology is commercially available. DarioHealth’s...
View ArticleClik here to view.
Fifth patient treated in Flowonix, Cerebral Therapeutics epilepsy study
Flowonix Medical and Cerebral Therapeutics said today that the fifth patient was successfully treated in its Address trial, which features a micro-infusion device controlling drug delivery to a...
View ArticleClik here to view.
Report: Mylan to pony up $20m to Massachusetts in EpiPen settlement
Mylan (NSDQ:MYL) is slated to pay $20.3 million to the Massachusetts Medicaid program to resolve claims that it underpaid the program by misclassifying its EpiPen device, according to attorney general...
View ArticleClik here to view.
Eli Lilly’s Humalog Junior KwikPen diabetes drug-device combo launches in U.S.
Eli Lilly‘s (NYSE:LLY) Humalog Junior KwikPen insulin lispro injection is available in the U.S. by prescription for people with diabetes, the company said today. The drug-device combination product is...
View ArticleClik here to view.
Pavmed to drop 510(k), pursue de novo pathway for PortIO infusion system
Pavmed Inc. (NSDQ:PAVM) plans to drop the 510(k) application for its PortIO intraosseous infusion system and instead pursue a de novo pathway for its device, according to a document the company filed...
View ArticleClik here to view.
OptiNose sets terms for $100m IPO
OptiNose set terms for its IPO this week, according to a regulatory filing submitted to the SEC. The company plans to offer 6.3 million shares at $15 – $17 apiece and funds affiliated with Avista...
View ArticleClik here to view.
Inovio touts first-in-man Ph1 trial of Zika virus vaccine
Inovio Pharmaceuticals (NSDQ:INO) touted today positive safety and immune response data from the first-in-man Phase I trial of its vaccine against the Zika virus. The trial showed that Inovio’s...
View Article